Osteoarthritis: A metabolic disease induced by local abnormal leptin activity? Daniel LajeunesseJean-Pierre PelletierJohanne Martel-Pelletier Invited Commentary Pages: 1 - 3
Outcomes and disease activity measures for assessing treatments in the idiopathic inflammatory myopathies Chester V. Oddis OriginalPaper Pages: 87 - 93
Interstitial lung disease in polymyositis and dermatomyositis Armin SchnabelBernhard HellmichWolf gang Ludwig Gross OriginalPaper Pages: 99 - 105
Exercise: An important component of treatment in the idiopathic inflammatory myopathies Helene Alexanderson OriginalPaper Pages: 115 - 124
New hope for systemic sclerosis patients with digital ulcers John Varga Clinical Trials Report Pages: 127 - 128
Clinical aspects of lung involvement: Lessons from idiopathic pulmonary fibrosis and the scleroderma lung study Kristin B. HighlandRichard M. Silver OriginalPaper Pages: 135 - 141
Immunomodulatory therapy for SSc: Will high-intensity immunosuppression with stem cell rescue improve outcome? Leslie J. Crofford OriginalPaper Pages: 142 - 149
Scleroderma, fibroblasts, signaling, and excessive extracellular matrix Hironobu Ihn OriginalPaper Pages: 156 - 162